Anatomy of the sternum and humerus in the domestic chicken (Gallus domesticus).

Injuries of the sternum and humerus are an important welfare concern in domestic chickens (Gallus domesticus), especially laying hens. Published anatomic references using standardized terminology from the Nomina Anatomica Avium (NAA) are lacking. Objectives of the current retrospective, descriptive study were to provide a user-friendly hierarchical table of NAA-compliant anatomic terms and labeled images illustrating anatomic structures for the sternum and humerus of domestic chickens. Three-dimensional model images were downloaded from a publicly accessible platform, labeled in consultation with a veterinary anatomist, and enhanced by a medical illustrator. Findings can serve as a resource for future clinical and research applications.

Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support.

Percutaneous mechanical circulatory support (MCS) devices, including the intraaortic balloon pump, Impella, and TandemHeart, are often used for hemodynamic support in the setting of refractory cardiogenic shock. The thrombotic and bleeding complications associated with these devices is well recognized, and the Impella and TandemHeart devices have unique anticoagulation considerations that may influence patient outcomes. Both devices typically require use of a heparinized purge solution in combination with intravenous unfractionated heparin, thereby providing multiple sources of heparin exposure. Each device also has specific monitoring requirements and goal ranges. This review provides an overview of percutaneous MCS devices commonly used in the acute management of left ventricular failure, with an emphasis on pharmacologic considerations. We review recent evidence and guidelines and provide recommendations for appropriate use of anticoagulation during device support. Approaches to managing heparinized purge solutions, monitoring, and the utility of nonheparin anticoagulants are also provided because high-quality evidence in the literature is limited.

Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.

PURPOSE: To critically evaluate current literature, review pharmacology, and discuss clinical role of ivabradine for patients with heart failure (HF) with reduced ejection fraction. DATA SOURCES: A PubMed search was conducted using the search terms ivabradine and HF. All human studies analyzing the use of ivabradine in patients with HF with reduced ejection fraction and prescribing information were evaluated. CONCLUSIONS: Greater benefit was seen in the prespecified subgroup with heart rate (HR) > 70 beats per minute (bpm) in the BEAUTIFUL study. Therefore, SHIFT examined the effect of ivabradine on patients with higher resting HR, lower ejection fraction, who had been hospitalized for HF within the previous year. A significant difference was found in the composite primary endpoint of cardiovascular death and hospitalizations for worsening HF in patients with HF and left ventricular systolic dysfunction, driven primarily by reduction in hospitalizations for worsening HF. The most common adverse effect was bradycardia. IMPLICATIONS FOR PRACTICE: Ivabradine is a safe and effective medication for HR reduction to reduce hospitalizations in patients with stable, symptomatic HF (ejection fraction < 35%), in sinus rhythm, and HR > 70 bpm.

Hepatitis B virus seroconversion rates among health sciences students in the southeastern United States.

OBJECTIVE: To investigate the hepatitis B virus (HBV) seroconversion rate among health sciences students. PARTICIPANTS: The study included pharmacy, doctor of nursing, and medical students over 18 years of age enrolled at the University of South Carolina between 2007 and 2011. METHODS: The primary end point was HBV seroconversion rates among students at the initial reporting period. Seroconversion was defined as hepatitis B surface antibody (anti-HBs) level greater than or equal to 10 mIU/mL. Multivariate regression analysis was used to determine predictive factors of seroconversion. RESULTS: Of 777 records, data were available for 709 students. An 83.9% seroconversion rate was observed after a mean of 10 years between vaccine receipt and anti-HBs evaluation. Students with incomplete HBV vaccine series and longer time between initial series and evaluation were less likely to exhibit antibody response. CONCLUSIONS: These data highlight the importance of assessment and documentation of HBV vaccination series among health sciences students prior to direct patient care activities.